Clinical Trials

Multiple clinical trials spanning Phase 1 through Phase 4 and phase-unspecified designs have evaluated Naratriptan HCl for headache disorders—such as migraine, post-traumatic headache, and status migrainosus—as well as pregnancy monitoring and select psychiatric conditions. Sponsored by industry leaders and academic medical centers, these protocols encompass completed, terminated, withdrawn, and unknown recruitment statuses.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03066544 UNKNOWN
Migraine
Hartford HealthCare
 2016-11-30 PHASE1; PHASE2
NCT01726920 WITHDRAWN
Migraine; Headache
Ache Laboratorios Farmaceuticos S.A.
 2014-07 PHASE3
NCT00282165 TERMINATED
Psychotic Disorders; Antisocial Personality Disorder; Impulse Regulation Disorder; Intermittent Explosive Disorder
UMC Utrecht
 2006-11 PHASE4
NCT01390324 WITHDRAWN
Migraine; Headache
Ache Laboratorios Farmaceuticos S.A.
 2011-12 PHASE3
NCT00487578 TERMINATED
Post Traumatic Headache
Cady, Roger, M.D.
 2006-10 PHASE4
NCT01161667 COMPLETED
Migraine
Roxane Laboratories
 2007-09
NCT01161654 COMPLETED
Migraine
Roxane Laboratories
 2007-08

(data from https://clinicaltrials.gov, updated on 2018-08-31)

Check the Naratriptan HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Naratriptan HCl selectively binds to and activates 5-hydroxytryptamine-1 receptor subtypes on cranial blood vessels and sensory nerve terminals, which suppresses adenylyl cyclase activity and blocks the release of pro-inflammatory neuropeptides. This molecular cascade produces intracranial vasoconstriction and attenuates neurogenic inflammation, providing therapeutic relief for patients suffering from migraine and post-traumatic headache conditions.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.